Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Liver Cirrhosis

  Free Subscription


Articles published in Hepatology

Retrieve available abstracts of 216 articles:
HTML format
Text format



Single Articles


    November 2017
  1. CHANG FM, Wang YP, Lu CL
    Reply: Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study.
    Hepatology. 2017 Nov 24. doi: 10.1002/hep.29686.
    PubMed     Text format    


  2. LIN CY
    Statins and risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: Methodological issues.
    Hepatology. 2017 Nov 24. doi: 10.1002/hep.29687.
    PubMed     Text format    


  3. LO GH, Reiberger T
    Peptic ulcer bleeding in cirrhotic patients: Is as bad as variceal bleeding?
    Hepatology. 2017 Nov 23. doi: 10.1002/hep.29680.
    PubMed     Text format     Abstract available


  4. TAPPER EB, Parikh N, Sengupta N, Mellinger J, et al
    A Risk Score to Predict the Development of Hepatic Encephalopathy in a Population-Based Cohort of Patients with Cirrhosis.
    Hepatology. 2017 Nov 1. doi: 10.1002/hep.29628.
    PubMed     Text format     Abstract available


  5. XIAO G, Zhu S, Xiao X, Yan L, et al
    Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis.
    Hepatology. 2017;66:1486-1501.
    PubMed     Text format     Abstract available


    October 2017
  6. PRAKTIKNJO M, Book M, Luetkens J, Pohlmann A, et al
    Fat-free muscle mass in magnetic resonance imaging predicts acute-on-chronic liver failure and survival in decompensated cirrhosis.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29602.
    PubMed     Text format     Abstract available


  7. PHILIPS CA, Kumar L, Augustine P
    Partial Splenic Artery Embolization for Severe Hepatic Myelopathy in Cirrhosis.
    Hepatology. 2017 Oct 23. doi: 10.1002/hep.29597.
    PubMed     Text format     Abstract available


  8. YANG JD, Mannalithara A, Piscitello AJ, Kisiel JB, et al
    Impact of Surveillance for Hepatocellular Carcinoma on Survival in Patients with Compensated Cirrhosis.
    Hepatology. 2017 Oct 12. doi: 10.1002/hep.29594.
    PubMed     Text format     Abstract available


  9. MONTANO-LOZA AJ, Mazurak VC, Ebadi M, Meza-Junco J, et al
    Visceral adiposity increases risk for hepatocellular carcinoma in male patients with cirrhosis and recurrence after liver transplant.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29578.
    PubMed     Text format     Abstract available


  10. MACDONALD S, Andreola F, Bachtiger P, Amoros A, et al
    Cell death markers in cirrhotic patients with acute decompensation.
    Hepatology. 2017 Oct 10. doi: 10.1002/hep.29581.
    PubMed     Text format     Abstract available


  11. ALBILLOS A, Zamora J, Martinez J, Arroyo D, et al
    Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis.
    Hepatology. 2017;66:1219-1231.
    PubMed     Text format     Abstract available


  12. SO-ARMAH KA, Lim JK, Lo Re V, Tate JP, et al
    FIB-4 stage of liver fibrosis predicts incident heart failure among HIV-infected and uninfected patients.
    Hepatology. 2017;66:1286-1295.
    PubMed     Text format     Abstract available


  13. BANGEN JM, Hammerich L, Sonntag R, Baues M, et al
    Targeting CCl4 -induced liver fibrosis by RNA interference-mediated inhibition of cyclin E1 in mice.
    Hepatology. 2017;66:1242-1257.
    PubMed     Text format     Abstract available


    September 2017
  14. WYLES D, Poordad F, Wang S, Alric L, et al
    Glecaprevir/Pibrentasvir for HCV Genotype 3 Patients with Cirrhosis and/or Prior Treatment Experience: A Partially Randomized Phase III Clinical Trial.
    Hepatology. 2017 Sep 19. doi: 10.1002/hep.29541.
    PubMed     Text format     Abstract available


  15. CESARI M, Frigo AC, Tonon M, Angeli P, et al
    Cardiovascular predictors of death in patients with cirrhosis.
    Hepatology. 2017 Sep 13. doi: 10.1002/hep.29520.
    PubMed     Text format     Abstract available


  16. BORENTAIN P, Colson P, Bolon E, Gauchez P, et al
    Hepatocellular carcinoma complicating hepatitis E virus-related cirrhosis.
    Hepatology. 2017 Sep 5. doi: 10.1002/hep.29508.
    PubMed     Text format    


    August 2017
  17. DE HAAS RJ, Lim C, Bhangui P, Salloum C, et al
    Curative Salvage Liver Transplantation in Cirrhotic patients with Hepatocellular Carcinoma: An intention-to-treat analysis.
    Hepatology. 2017 Aug 14. doi: 10.1002/hep.29468.
    PubMed     Text format     Abstract available


  18. LAI JC, Covinsky KE, Dodge JL, Boscardin WJ, et al
    Development of a novel frailty index to predict mortality in patients with end-stage liver disease.
    Hepatology. 2017;66:564-574.
    PubMed     Text format     Abstract available


    July 2017
  19. SAUERBRUCH T
    Continuation of non-selective beta-blockers for patients with liver cirrhosis and hemodynamic non-response?
    Hepatology. 2017 Jul 22. doi: 10.1002/hep.29394.
    PubMed     Text format    


  20. PEDERSEN JS, Kimer N, Henriksen JH, Bendtsen F, et al
    The Royal Free Hospital Cirrhosis Glomerular Filtration Rate: Validation in a Danish Cohort.
    Hepatology. 2017 Jul 20. doi: 10.1002/hep.29386.
    PubMed     Text format    


  21. KALAFATELI M, Tsochatzis EA
    Reply to "The Royal Free Hospital Cirrhosis Glomerular Filtration Rate: Validation in a Danish Cohort."
    Hepatology. 2017 Jul 20. doi: 10.1002/hep.29391.
    PubMed     Text format    


  22. ARDEVOL A, Ibanez-Sanz G, Profitos J, Aracil C, et al
    Survival of patients with cirrhosis and acute peptic ulcer bleeding compared with variceal bleeding using current first-line therapies.
    Hepatology. 2017 Jul 17. doi: 10.1002/hep.29370.
    PubMed     Text format     Abstract available


  23. UNALP-ARIDA A, Ruhl CE
    Liver fibrosis scores predict liver disease mortality in the United States population.
    Hepatology. 2017;66:84-95.
    PubMed     Text format     Abstract available


    June 2017
  24. CHIDA T, Ito M, Nakashima K, Kanegae Y, et al
    Critical role of CREBH-mediated induction of TGF-beta2 by HCV infection in fibrogenic responses in hepatic stellate cells.
    Hepatology. 2017 Jun 16. doi: 10.1002/hep.29319.
    PubMed     Text format     Abstract available


    May 2017
  25. MARKWARDT D, Holdt L, Steib C, Benesic A, et al
    Plasma Cystatin C is a predictor of renal dysfunction, ACLF and mortality in patients with acutely decompensated liver cirrhosis.
    Hepatology. 2017 May 25. doi: 10.1002/hep.29290.
    PubMed     Text format     Abstract available


  26. TSOCHATZIS EA, Bosch J
    Statins in cirrhosis - ready for prime time.
    Hepatology. 2017 May 22. doi: 10.1002/hep.29277.
    PubMed     Text format    


    April 2017
  27. SONG Y, Liu C, Liu X, Trottier J, et al
    H19 promotes cholestatic liver fibrosis by preventing ZEB1-mediated inhibition of EpCAM.
    Hepatology. 2017 Apr 13. doi: 10.1002/hep.29209.
    PubMed     Text format     Abstract available


  28. HADJIHAMBI A, De Chiara F, Hosford PS, Habtetion A, et al
    Ammonia mediates cortical hemichannel dysfunction in rodent models of chronic liver disease.
    Hepatology. 2017;65:1306-1318.
    PubMed     Text format     Abstract available


  29. BALIGAR P, Kochat V, Arindkar SK, Equbal Z, et al
    Bone marrow stem cell therapy partially ameliorates pathological consequences in livers of mice expressing mutant human alpha1-antitrypsin.
    Hepatology. 2017;65:1319-1335.
    PubMed     Text format     Abstract available


  30. HALL Z, Bond NJ, Ashmore T, Sanders F, et al
    Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease.
    Hepatology. 2017;65:1165-1180.
    PubMed     Text format     Abstract available


  31. PETTA S, Wong VW, Camma C, Hiriart JB, et al
    Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values.
    Hepatology. 2017;65:1145-1155.
    PubMed     Text format     Abstract available


    March 2017
  32. CHANG FM, Wang YP, Lang HC, Tsai CF, et al
    Statins decrease the risk of decompensation in HBV- and HCV-related cirrhosis: A population-based study.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29172.
    PubMed     Text format     Abstract available


  33. DE MATTOS AZ, Miozzo SA, Tovo CV, de Mattos AA, et al
    Risks of proton pump inhibitors for cirrhotic patients - the controversy remains.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29132.
    PubMed     Text format    


  34. MOLLER S, Hove JD
    Assessment of systolic function in the evaluation of patients with cirrhosis.
    Hepatology. 2017 Mar 20. doi: 10.1002/hep.29163.
    PubMed     Text format    


  35. CAMPAGNA F, Montagnese S, Ridola L, Senzolo M, et al
    The animal naming test: An easy tool for the assessment of hepatic encephalopathy.
    Hepatology. 2017 Mar 8. doi: 10.1002/hep.29146.
    PubMed     Text format     Abstract available


  36. LI X, Liu R, Yang J, Sun L, et al
    The role of LncRNA H19 in gender disparity of cholestatic liver injury in Mdr2-/- mice.
    Hepatology. 2017 Mar 8. doi: 10.1002/hep.29145.
    PubMed     Text format     Abstract available


  37. WAN Y, Meng F, Wu N, Zhou T, et al
    Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells.
    Hepatology. 2017 Mar 3. doi: 10.1002/hep.29138.
    PubMed     Text format     Abstract available


  38. MAIERS JL, Kostallari E, Mushref M, deAssuncao TM, et al
    The unfolded protein response mediates fibrogenesis and collagen I secretion through regulating TANGO1 in mice.
    Hepatology. 2017;65:983-998.
    PubMed     Text format     Abstract available


  39. ZHU B, Wei L, Rotile N, Day H, et al
    Combined magnetic resonance elastography and collagen molecular magnetic resonance imaging accurately stage liver fibrosis in a rat model.
    Hepatology. 2017;65:1015-1025.
    PubMed     Text format     Abstract available


  40. KISSELEVA T
    The origin of fibrogenic myofibroblasts in fibrotic liver.
    Hepatology. 2017;65:1039-1043.
    PubMed     Text format     Abstract available


    February 2017
  41. DAM G, Vilstrup H, Watson H, Jepsen P, et al
    Reply to letter from de Mattos and colleagues: Risks of proton pump inhibitors for cirrhotic patients - the controversy remains.
    Hepatology. 2017 Feb 21. doi: 10.1002/hep.29131.
    PubMed     Text format    


  42. YOTTI R, Ripoll C, Benito Y, Catalina MV, et al
    Left ventricular systolic function is associated to sympathetic nervous activity and markers of inflammation in cirrhosis.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29104.
    PubMed     Text format     Abstract available


  43. KUMAR A, Davuluri G, deSilva RN, Engelen MP, et al
    Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29107.
    PubMed     Text format    


  44. BRUDEN DJ, McMahon BJ, Townshend-Bulson L, Gounder P, et al
    Risk of End Stage Liver Disease, Hepatocellular Carcinoma and Liver-Related Death By Fibrosis Stage in the Hepatitis C Alaska Cohort.
    Hepatology. 2017 Feb 13. doi: 10.1002/hep.29115.
    PubMed     Text format     Abstract available


  45. FERNANDEZ CARRILLO C, Lens S, Llop E, Pascasio JM, et al
    Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of MELD: Analysis of data from the Hepa-C registry.
    Hepatology. 2017 Feb 7. doi: 10.1002/hep.29097.
    PubMed     Text format     Abstract available


  46. ZUBIETE-FRANCO I, Fernandez-Tussy P, Barbier-Torres L, Simon J, et al
    Deregulated neddylation in liver fibrosis.
    Hepatology. 2017;65:694-709.
    PubMed     Text format     Abstract available


  47. TEDESCO D, Thapa M, Gumber S, Elrod EJ, et al
    CD4+ Foxp3+ T cells promote aberrant immunoglobulin G production and maintain CD8+ T-cell suppression during chronic liver disease.
    Hepatology. 2017;65:661-677.
    PubMed     Text format     Abstract available


    January 2017
  48. VILASECA M, Garcia-Caldero H, Lafoz E, Garcia-Irigoyen O, et al
    The anticoagulant Rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.
    Hepatology. 2017 Jan 31. doi: 10.1002/hep.29084.
    PubMed     Text format     Abstract available


  49. WANG Y, Vincent R, Yang J, Asgharpour A, et al
    Dual photon microscopy based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis.
    Hepatology. 2017 Jan 30. doi: 10.1002/hep.29090.
    PubMed     Text format     Abstract available


  50. WANG Y, Aoki H, Yang J, Peng K, et al
    The role of S1PR2 in bile acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice.
    Hepatology. 2017 Jan 24. doi: 10.1002/hep.29076.
    PubMed     Text format     Abstract available


  51. HARGROVE L, Kennedy L, Demieville J, Jones H, et al
    BDL-induced biliary hyperplasia, hepatic injury and fibrosis are reduced in mast cell deficient Kitw-sh mice.
    Hepatology. 2017 Jan 24. doi: 10.1002/hep.29079.
    PubMed     Text format     Abstract available


  52. THABET K, Chan HL, Petta S, Mangia A, et al
    The MBOAT7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B.
    Hepatology. 2017 Jan 20. doi: 10.1002/hep.29064.
    PubMed     Text format     Abstract available


  53. SABATE A, Blasi A
    Thromboelastography and blood product usage in cirrhosis with severe coagulopathy.
    Hepatology. 2017 Jan 19. doi: 10.1002/hep.29061.
    PubMed     Text format    


  54. VILLANUEVA C, Graupera I, Aracil C, Alvarado E, et al
    A Randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis.
    Hepatology. 2017 Jan 18. doi: 10.1002/hep.29056.
    PubMed     Text format     Abstract available


  55. DRIVER R, Rowe IA
    What is the benefit of early follow-up after hospitalization for patients with cirrhosis?
    Hepatology. 2017 Jan 18. doi: 10.1002/hep.29060.
    PubMed     Text format    


  56. MARONI L, Hohenester SD, van de Graaf SF, Tolenaars D, et al
    Knockout of the Primary Sclerosing Cholangitis-Risk Gene Fut2 Causes Liver Disease in Mice.
    Hepatology. 2017 Jan 5. doi: 10.1002/hep.29029.
    PubMed     Text format     Abstract available


  57. ALCARAZ-QUILES J, Titos E, Casulleras M, Pavesi M, et al
    Polymorphisms in the IL-1 gene cluster influence systemic inflammation in patients at risk for acute-on-chronic liver failure.
    Hepatology. 2017;65:202-216.
    PubMed     Text format     Abstract available


  58. DECARIS ML, Li KW, Emson CL, Gatmaitan M, et al
    Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood.
    Hepatology. 2017;65:78-88.
    PubMed     Text format     Abstract available


    December 2016
  59. TANDON P, Raman M, Mourtzakis M, Merli M, et al
    A Practical Approach to Nutritional Screening and Assessment in Cirrhosis.
    Hepatology. 2016 Dec 27. doi: 10.1002/hep.29003.
    PubMed     Text format     Abstract available


  60. BERZIGOTTI A, Albillos A, Villanueva C, Genesca J, et al
    Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The sportdiet study.
    Hepatology. 2016 Dec 20. doi: 10.1002/hep.28992.
    PubMed     Text format     Abstract available


  61. KAFFE E, Katsifa A, Xylourgidis N, Ninou I, et al
    Hepatocyte Autotaxin expression promotes liver fibrosis and cancer.
    Hepatology. 2016 Dec 16. doi: 10.1002/hep.28973.
    PubMed     Text format     Abstract available


    November 2016
  62. ASKGAARD G, Leon DA, Kjaer MS, Deleuran T, et al
    Risk for alcoholic liver cirrhosis after an initial hospital contact with alcohol problems: A nationwide prospective cohort study.
    Hepatology. 2016 Nov 16. doi: 10.1002/hep.28943.
    PubMed     Text format     Abstract available


  63. NEWBERRY EP, Xie Y, Kennedy SM, Graham MJ, et al
    Prevention of hepatic fibrosis with liver microsomal triglyceride transfer protein deletion in Liver fatty acid binding protein null mice.
    Hepatology. 2016 Nov 14. doi: 10.1002/hep.28941.
    PubMed     Text format     Abstract available


  64. CALDWELL S, Lisman T
    The cirrhotic platelet: Shedding light on an enigma.
    Hepatology. 2016 Nov 7. doi: 10.1002/hep.28931.
    PubMed     Text format    


  65. MASSEY VL, Dolin CE, Poole LG, Hudson SV, et al
    The hepatic "matrisome" responds dynamically to injury: Characterization of transitional changes to the extracellular matrix in mice.
    Hepatology. 2016 Nov 5. doi: 10.1002/hep.28918.
    PubMed     Text format     Abstract available


  66. DESBOROUGH MJ, Kahan BC, Stanworth SJ, Jairath V, et al
    Fibrinogen as an independent predictor of mortality in decompensated cirrhosis and bleeding.
    Hepatology. 2016 Nov 3. doi: 10.1002/hep.28915.
    PubMed     Text format    


  67. DROLZ A, Fuhrmann V
    "Fibrinogen as an independent predictor of mortality in decompensated cirrhosis and bleeding".
    Hepatology. 2016 Nov 3. doi: 10.1002/hep.28914.
    PubMed     Text format    


    October 2016
  68. GARCIA-TSAO G, Abraldes J, Berzigotti A, Bosch J, et al
    Portal Hypertensive Bleeding in Cirrhosis: Risk Stratification, Diagnosis and Management - 2016 Practice Guidance by the American Association for the Study of Liver Diseases.
    Hepatology. 2016 Oct 27. doi: 10.1002/hep.28906.
    PubMed     Text format    


  69. KALAFATELI M, Wickham F, Burniston M, Cholongitas E, et al
    Development and validation of a mathematical equation to estimate glomerular filtration rate in cirrhosis: The rfh cirrhosis Gfr.
    Hepatology. 2016 Oct 25. doi: 10.1002/hep.28891.
    PubMed     Text format     Abstract available


  70. TANDON P, Reddy KR, O'Leary JG, Garcia-Tsao G, et al
    A Karnofsky performance status-based score predicts death after hospital discharge in patients with cirrhosis.
    Hepatology. 2016 Oct 24. doi: 10.1002/hep.28900.
    PubMed     Text format     Abstract available


  71. ATIQ O, Tiro J, Yopp AC, Muffler A, et al
    An Assessment of Benefits and Harms of Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis.
    Hepatology. 2016 Oct 24. doi: 10.1002/hep.28895.
    PubMed     Text format     Abstract available


  72. KIMER N, Pedersen JS, Busk TM, Gluud LL, et al
    Rifaximin has no effect on hemodynamics in decompensated cirrhosis - A randomized, double blind, placebo controlled trial.
    Hepatology. 2016 Oct 24. doi: 10.1002/hep.28898.
    PubMed     Text format     Abstract available


  73. LABONTE AC, Sung SJ, Jennelle LT, Dandekar AP, et al
    Expression of scavenger receptor-AI promotes alternative activation of murine macrophages to limit hepatic inflammation and fibrosis.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28873.
    PubMed     Text format     Abstract available


  74. PARIKH ND, Marshall VD, Singal AG, Nathan H, et al
    Survival and Cost-Effectiveness of Sorafenib Therapy in Advanced Hepatocellular Carcinoma: An Analysis of the SEER-Medicare Database.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28881.
    PubMed     Text format     Abstract available


  75. WRANKE A, Calle Serrano B, Heidrich B, Kirschner J, et al
    Antiviral treatment and liver-related complications in hepatitis delta.
    Hepatology. 2016 Oct 22. doi: 10.1002/hep.28876.
    PubMed     Text format     Abstract available


  76. MAROT A, Vandenbulcke H, Knebel JF, Doerig C, et al
    External validation of the nomogram for individualized prediction of HCC occurrence in patients with HCV-related compensated cirrhosis.
    Hepatology. 2016 Oct 13. doi: 10.1002/hep.28865.
    PubMed     Text format    


    September 2016
  77. ALI KHAN M, Cholankeril G, Howden CW
    Are proton pump inhibitors a threat for spontaneous bacterial peritonitis and hepatic encephalopathy in cirrhosis? Not so fast.
    Hepatology. 2016 Sep 30. doi: 10.1002/hep.28858.
    PubMed     Text format    


  78. LO GH
    The risk of bleeding after invasive procedures in cirrhotics with severe coagulopathy.
    Hepatology. 2016 Sep 26. doi: 10.1002/hep.28855.
    PubMed     Text format    


  79. RAPARELLI V, Basili S, Carnevale R, Napoleone L, et al
    Low-grade endotoxemia and platelet activation in cirrhosis.
    Hepatology. 2016 Sep 19. doi: 10.1002/hep.28853.
    PubMed     Text format     Abstract available


  80. AMARAPURKAR D, Somani V, Shah A
    Do we need to correct coagulation abnormalities prophylactically in cirrhotics undergoing invasive procedures? - A Dilemma.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28830.
    PubMed     Text format    


  81. ABRALDES JG, Bureau C, Stefanescu H, Augustin S, et al
    Non-invasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The "Anticipate" study.
    Hepatology. 2016 Sep 17. doi: 10.1002/hep.28824.
    PubMed     Text format     Abstract available


  82. RENOU C, Lesgourgues B, Macaigne G, Pauwels A, et al
    Hepatitis E in decompensated alcoholic cirrhosis.
    Hepatology. 2016 Sep 12. doi: 10.1002/hep.28792.
    PubMed     Text format    


    August 2016
  83. LALEMAN W, Trebicka J, Verbeke L
    Evolving insights in the pathophysiology of complications of cirrhosis: The Farnesoid-X receptor (FXR) to the rescue?
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28771.
    PubMed     Text format    


  84. FARVARDIN S, Patel J, Khambaty M, Yerokun OA, et al
    Patient-Reported Barriers are Associated with Lower HCC Surveillance Rates in Patients with Cirrhosis.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28770.
    PubMed     Text format     Abstract available


  85. GOLDBERG DS, Taddei TH, Serper M, Mehta R, et al
    Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28765.
    PubMed     Text format     Abstract available


  86. SALLOUM S, Holmes JA, Jindal R, Bale SS, et al
    HIV/HCV in hepatic and stellate cell lines reveals cooperative profibrotic transcriptional activation between viruses and cell types.
    Hepatology. 2016 Aug 17. doi: 10.1002/hep.28766.
    PubMed     Text format     Abstract available


  87. BIHARI C, Anand L, Rooge S, Kumar D, et al
    Bone Marrow Stem Cells and its Niche Components are Adversely Affected in Advanced Cirrhosis of Liver.
    Hepatology. 2016 Aug 3. doi: 10.1002/hep.28754.
    PubMed     Text format     Abstract available


  88. CLARIA J, Stauber RE, Coenraad MJ, Moreau R, et al
    systemic inflammation in decompensated cirrhosis. Characterization and role in acute-on-chronic liver failure.
    Hepatology. 2016 Aug 2. doi: 10.1002/hep.28740.
    PubMed     Text format     Abstract available


  89. DROLZ A, Fuhrmann V
    Reply to "Anticoagulation with i.v. unfractionated heparin and major bleeding in cirrhosis".
    Hepatology. 2016 Aug 2. doi: 10.1002/hep.28757.
    PubMed     Text format    


    July 2016
  90. QI X, De Stefano V, Guo X
    Anticoagulation with i.v. unfractionated heparin and major bleeding in cirrhosis.
    Hepatology. 2016 Jul 30. doi: 10.1002/hep.28743.
    PubMed     Text format    


  91. DAM G, Vilstrup H, Watson H, Jepsen P, et al
    Proton Pump Inhibitors as a Risk Factor for Hepatic Encephalopathy and Spontaneous Bacterial Peritonitis in Cirrhosis Patients With Ascites.
    Hepatology. 2016 Jul 30. doi: 10.1002/hep.28737.
    PubMed     Text format     Abstract available


  92. MAROT A, Trepo E, Doerig C, Moreno C, et al
    SEMS should be considered in patients with cirrhosis and uncontrolled variceal bleeding.
    Hepatology. 2016 Jul 30. doi: 10.1002/hep.28738.
    PubMed     Text format    


  93. LANGBERG KM, Taddei TH
    Balancing quality with quantity: The role of palliative care in managing decompensated cirrhosis.
    Hepatology. 2016 Jul 7. doi: 10.1002/hep.28717.
    PubMed     Text format    


    June 2016
  94. KALAMBOKIS GN, Oikonomou A, Christou L, Baltayiannis G, et al
    High von Willebrand factor antigen levels and procoagulant imbalance may be involved in both increasing severity of cirrhosis and portal vein thrombosis.
    Hepatology. 2016 Jun 27. doi: 10.1002/hep.28703.
    PubMed     Text format    


  95. GANNE-CARRIE N, Layese R, Bourcier V, Cagnot C, et al
    Nomogram for individualized prediction of hepatocellular carcinoma occurrence in HCV-cirrhosis (ANRS CO12 CirVir).
    Hepatology. 2016 Jun 27. doi: 10.1002/hep.28702.
    PubMed     Text format     Abstract available


  96. KANG DJ, Betrapally NS, Ghosh SA, Sartor RB, et al
    Gut microbiota drive the development of neuro-inflammatory response in cirrhosis.
    Hepatology. 2016 Jun 23. doi: 10.1002/hep.28696.
    PubMed     Text format     Abstract available


  97. SUK KT, Yoon JH, Kim MY, Kim CW, et al
    Transplantation with Autologous Bone Marrow-Derived Mesenchymal Stem Cells for Alcoholic Cirrhosis: Phase 2 Trial.
    Hepatology. 2016 Jun 23. doi: 10.1002/hep.28693.
    PubMed     Text format     Abstract available


  98. ULVELING D, Le Clerc S, Cobat A, Labib T, et al
    A new 3p25 locus is associated with liver fibrosis progression in HIV/HCV co-infected patients.
    Hepatology. 2016 Jun 23. doi: 10.1002/hep.28695.
    PubMed     Text format     Abstract available


  99. CUI J, Chen CH, Lo MT, Schork N, et al
    Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study.
    Hepatology. 2016 Jun 17. doi: 10.1002/hep.28674.
    PubMed     Text format     Abstract available


  100. DI PASCOLI M, Zampieri F, Verardo A, Pesce P, et al
    Inhibition of EETs production in cirrhotic rats has beneficial effects on portal hypertension by reducing splanchnic vasodilation.
    Hepatology. 2016 Jun 16. doi: 10.1002/hep.28686.
    PubMed     Text format     Abstract available


  101. SETIAWAN VW, Stram DO, Porcel J, Lu SC, et al
    Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The Multiethnic Cohort.
    Hepatology. 2016 Jun 15. doi: 10.1002/hep.28677.
    PubMed     Text format     Abstract available


    May 2016
  102. MATSUURA K, De Giorgi V, Schechterly C, Wang RY, et al
    Circulating let-7 levels in plasma and extracellular vesicles correlate with hepatic fibrosis progression in chronic hepatitis C.
    Hepatology. 2016 May 26. doi: 10.1002/hep.28660.
    PubMed     Text format     Abstract available


  103. PAPATHEODORIDIS G, Vlachogiannakos I, Cholongitas E, Wursthorn K, et al
    Discontinuation of oral antivirals in chronic hepatitis B: A systematic review.
    Hepatology. 2016;63:1481-1492.
    PubMed     Text format     Abstract available


  104. LIASKOU E, Klemsdal Henriksen EK, Holm K, Kaveh F, et al
    High-throughput T-cell receptor sequencing across chronic liver diseases reveals distinct disease-associated repertoires.
    Hepatology. 2016;63:1608-19.
    PubMed     Text format     Abstract available


    April 2016
  105. DROLZ A, Horvatits T, Roedl K, Rutter K, et al
    Coagulation parameters and major bleeding in critically ill patients with cirrhosis.
    Hepatology. 2016 Apr 28. doi: 10.1002/hep.28628.
    PubMed     Text format     Abstract available


  106. TANG H, Bai HX, Su C, Lee AM, et al
    The effect of cirrhosis on radiogenomic biomarker's ability to predict microvascular invasion and outcome in hepatocellular carcinoma.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28620.
    PubMed     Text format    


  107. MALIZIA G, Cervello OV, D'Amico G
    Statins in cirrhosis: The magic pill?
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28616.
    PubMed     Text format    


  108. WU N, Meng F, Invernizzi P, Bernuzzi F, et al
    The secretin/secretin receptor axis modulates liver fibrosis through changes in TGF-beta1 biliary secretion.
    Hepatology. 2016 Apr 26. doi: 10.1002/hep.28622.
    PubMed     Text format     Abstract available


  109. LIU J, Yang HI, Lee MH, Jen CL, et al
    Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression.
    Hepatology. 2016 Apr 15. doi: 10.1002/hep.28552.
    PubMed     Text format     Abstract available


  110. LI KK, Trivedi PJ, Von Heimendahl S, Bruns T, et al
    Hepatocellular carcinoma surveillance in hepatitis B virus-infected individuals: Who and how?
    Hepatology. 2016;63:1394-5.
    PubMed     Text format    


  111. BARTNECK M, Fech V, Ehling J, Govaere O, et al
    Histidine-rich glycoprotein promotes macrophage activation and inflammation in chronic liver disease.
    Hepatology. 2016;63:1310-24.
    PubMed     Text format     Abstract available


  112. PIANO S, Fasolato S, Salinas F, Romano A, et al
    The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial.
    Hepatology. 2016;63:1299-309.
    PubMed     Text format     Abstract available


    March 2016
  113. KALAMBOKIS GN, Christodoulou D, Baltayiannis G, Christou L, et al
    Propranolol use beyond 6 months increases mortality in patients with Child-Pugh C cirrhosis and ascites.
    Hepatology. 2016 Mar 26. doi: 10.1002/hep.28575.
    PubMed     Text format    


  114. KANWAL F, Asch SM, Kramer JR, Cao Y, et al
    Early Outpatient Follow-up and 30-day Outcomes in Patients Hospitalized with Cirrhosis.
    Hepatology. 2016 Mar 17. doi: 10.1002/hep.28558.
    PubMed     Text format     Abstract available


  115. MCPHAIL MJ, Auzinger G, Bernal W, Wendon JA, et al
    Decisions on futility in patients with cirrhosis and organ failure.
    Hepatology. 2016 Mar 7. doi: 10.1002/hep.28539.
    PubMed     Text format    


  116. GUSTOT T, Fernandez J, Pavesi M, Arroyo V, et al
    Reply to "Decisions on futility in patients with cirrhosis and organ failure".
    Hepatology. 2016 Mar 7. doi: 10.1002/hep.28538.
    PubMed     Text format    


    February 2016
  117. SIMON TG, Bonilla H, Yan P, Chung RT, et al
    Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and HCC, among patients with HCV Results from ERCHIVES.
    Hepatology. 2016 Feb 18. doi: 10.1002/hep.28506.
    PubMed     Text format     Abstract available


  118. VILARINHO S, Sari S, Yilmaz G, Stiegler AL, et al
    Recurrent Recessive Mutation in DGUOK Causes Idiopathic Non-Cirrhotic Portal Hypertension.
    Hepatology. 2016 Feb 13. doi: 10.1002/hep.28499.
    PubMed     Text format     Abstract available


  119. CUI J, Heba E, Hernandez C, Haufe W, et al
    Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: A prospective study.
    Hepatology. 2016;63:453-61.
    PubMed     Text format     Abstract available


    January 2016
  120. LEROY V, Angus P, Bronowicki JP, Dore GJ, et al
    Daclatasvir, Sofosbuvir, and Ribavirin for Hepatitis C Virus Genotype 3 and Advanced Liver Disease: A Randomized Phase III Study (ALLY-3+).
    Hepatology. 2016 Jan 28. doi: 10.1002/hep.28473.
    PubMed     Text format     Abstract available


  121. TAPPER EB
    Challenge accepted: Confronting readmissions for our patients with cirrhosis.
    Hepatology. 2016 Jan 25. doi: 10.1002/hep.28471.
    PubMed     Text format    


  122. SACK J, Garcia-Tsao G
    Variceal hemorrhage in a patient with HCV cirrhosis in whom liver synthetic function had normalized after viral elimination.
    Hepatology. 2016 Jan 25. doi: 10.1002/hep.28470.
    PubMed     Text format    


  123. KWO P, Gitlin N, Nahass R, Bernstein D, et al
    Simeprevir Plus Sofosbuvir (12 and 8 Weeks) in HCV Genotype 1-Infected Patients Without Cirrhosis: OPTIMIST-1, a Phase 3, Randomized Study.
    Hepatology. 2016 Jan 22. doi: 10.1002/hep.28467.
    PubMed     Text format     Abstract available


  124. NORONHA FERREIRA C, Seijo S, Plessier A, Silva-Junior G, et al
    Natural history and management of esophagogastric varices in chronic non-cirrhotic non-tumoral portal vein thrombosis.
    Hepatology. 2016 Jan 22. doi: 10.1002/hep.28466.
    PubMed     Text format     Abstract available


  125. POORDAD F, Schiff ER, Vierling JM, Landis C, et al
    Daclatasvir With Sofosbuvir and Ribavirin for HCV Infection With Advanced Cirrhosis or Post-Liver Transplant Recurrence.
    Hepatology. 2016 Jan 11. doi: 10.1002/hep.28446.
    PubMed     Text format     Abstract available


  126. DESAI SS, Tung JC, Zhou VX, Grenert JP, et al
    Physiological Ranges of Matrix Rigidity Modulate Primary Mouse Hepatocyte Function In Part Through Hepatocyte Nuclear Factor 4 Alpha.
    Hepatology. 2016 Jan 11. doi: 10.1002/hep.28450.
    PubMed     Text format     Abstract available



  127. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta-analysis.
    Hepatology. 2016;63:349.
    PubMed     Text format    


  128. GIANNINI EG, Stravitz RT, Caldwell SH
    Portal vein thrombosis and chronic liver disease progression: The closer you look the more you see.
    Hepatology. 2016;63:342-3.
    PubMed     Text format    


  129. KOEHLER EM, Plompen EP, Schouten JN, Hansen BE, et al
    Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study.
    Hepatology. 2016;63:138-47.
    PubMed     Text format     Abstract available


    December 2015
  130. OH Y, Park O, Swierczewska M, Hamilton JP, et al
    Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells.
    Hepatology. 2015 Dec 28. doi: 10.1002/hep.28432.
    PubMed     Text format     Abstract available


  131. REIN DB, Borton J, Liffmann DK, Wittenborn JS, et al
    The burden of hepatitis C to the United States medicare system in 2009: Descriptive and economic characteristics.
    Hepatology. 2015 Dec 28. doi: 10.1002/hep.28430.
    PubMed     Text format     Abstract available


  132. INTAGLIATA NM, Caldwell SH, Porte RJ, Lisman T, et al
    Prediction of bleeding in cirrhosis patients: Is the forecast any clearer?
    Hepatology. 2015 Dec 24. doi: 10.1002/hep.28426.
    PubMed     Text format    


  133. LAWITZ E, Matusow G, DeJesus E, Yoshida EM, et al
    Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A Phase 3 study (OPTIMIST-2).
    Hepatology. 2015 Dec 24. doi: 10.1002/hep.28422.
    PubMed     Text format     Abstract available


  134. TANOUE S, Kaplan DE
    CD14 regulatory Dendritic Cells in Hepatocellular Carcinoma and Cirrhotic patients.
    Hepatology. 2015 Dec 24. doi: 10.1002/hep.28419.
    PubMed     Text format    


  135. SAAB S, Park SH, Mizokami M, Omata M, et al
    Safety and Efficacy of Ledipasvir/Sofosbuvir for the Treatment of Genotype 1 Hepatitis C in Subjects Aged 65 Years or Older.
    Hepatology. 2015 Dec 24. doi: 10.1002/hep.28425.
    PubMed     Text format     Abstract available


  136. BAJAJ JS, Reddy KR, Tandon P, Wong F, et al
    The Three-Month Readmission Rate Remains Unacceptably High in a Large North American Cohort of Cirrhotic Patients.
    Hepatology. 2015 Dec 21. doi: 10.1002/hep.28414.
    PubMed     Text format     Abstract available


  137. LOCATELLI L, Cadamuro M, Spirli C, Fiorotto R, et al
    Macrophage recruitment by fibrocystin-defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis.
    Hepatology. 2015 Dec 8. doi: 10.1002/hep.28382.
    PubMed     Text format     Abstract available


    November 2015
  138. BLASI A, Hernandez-Gea V, Reverter JC, Garcia-Pagan JC, et al
    Quality of anticoagulation and outcome of bleeding in cirrhosis.
    Hepatology. 2015 Nov 25. doi: 10.1002/hep.28371.
    PubMed     Text format    


  139. QI X, De Stefano V, Guo X
    Quality of anticoagulation and outcome of bleeding in cirrhosis.
    Hepatology. 2015 Nov 25. doi: 10.1002/hep.28369.
    PubMed     Text format    


  140. BOSSEN L, Krag A, Vilstrup H, Watson H, et al
    Non-selective beta-blockers do not affect mortality in cirrhosis patients with ascites: Post hoc analysis of three RCTs with 1198 patients.
    Hepatology. 2015 Nov 24. doi: 10.1002/hep.28352.
    PubMed     Text format     Abstract available


  141. LOK AS, McMahon BJ, Brown RS Jr, Wong JB, et al
    Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis.
    Hepatology. 2015 Nov 13. doi: 10.1002/hep.28280.
    PubMed     Text format     Abstract available


  142. DESBOROUGH MJ, Jairath V
    Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy.
    Hepatology. 2015 Nov 6. doi: 10.1002/hep.28336.
    PubMed     Text format    


  143. MERLI M, Lucidi C, Di Gregorio V, Lattanzi B, et al
    An empirical broad spectrum antibiotic therapy in Healthcare-Associated infections improves survival in cirrhotics: A randomized trial.
    Hepatology. 2015 Nov 3. doi: 10.1002/hep.28332.
    PubMed     Text format     Abstract available


  144. FERNANDEZ J, Tandon P, Mensa J, Garcia-Tsao G, et al
    Antibiotic prophylaxis in cirrhosis: Good and bad.
    Hepatology. 2015 Nov 3. doi: 10.1002/hep.28330.
    PubMed     Text format     Abstract available


  145. LEUNG DH, Khan M, Minard CG, Guffey D, et al
    Aspartate aminotransferase to platelet ratio and fibrosis-4 as biomarkers in biopsy-validated pediatric cystic fibrosis liver disease.
    Hepatology. 2015;62:1576-83.
    PubMed     Text format     Abstract available


    October 2015
  146. LEE MS
    Clinical characteristics and outcomes of pyogenic vertebral osteomyelitis in patients with cirrhosis.
    Hepatology. 2015 Oct 30. doi: 10.1002/hep.28319.
    PubMed     Text format    


  147. LAI JC, Dodge JL, Sen S, Covinsky K, et al
    Functional Decline in Patients with Cirrhosis Awaiting Liver Transplantation: Results from the Functional Assessment in Liver Transplantation (FrAILT) Study.
    Hepatology. 2015 Oct 30. doi: 10.1002/hep.28316.
    PubMed     Text format     Abstract available


  148. BURZA MA, Motta BM, Mancina RM, Pingitore P, et al
    DEPDC5 variants increase fibrosis progression in Europeans with chronic HCV infection.
    Hepatology. 2015 Oct 30. doi: 10.1002/hep.28322.
    PubMed     Text format     Abstract available


  149. ALBILLOS A, Martinez J, Tellez L
    Continued controversy over the safety of beta-blockers in decompensated cirrhosis.
    Hepatology. 2015 Oct 16. doi: 10.1002/hep.28293.
    PubMed     Text format    


  150. RAHIMI RS, O'Leary JG
    Transfusing Common Sense Instead of Blood Products into Coagulation Testing in Patients with Cirrhosis: Overtreatment not equal Safety.
    Hepatology. 2015 Oct 16. doi: 10.1002/hep.28291.
    PubMed     Text format    


  151. AHMED A, Perumpail RB, Harrison SA
    High Prevalence of Hepatic Fibrosis in the Setting of Coexisting Diabetes and Hepatic Steatosis: A Case for Selective Screening in General Population?
    Hepatology. 2015 Oct 9. doi: 10.1002/hep.28277.
    PubMed     Text format    


  152. RIPOLL C
    Non-invasive predictors of fibrosis in NASH with and without cirrhosis, just as good as histology (and HVPG?).
    Hepatology. 2015 Oct 8. doi: 10.1002/hep.28273.
    PubMed     Text format    


  153. PENG ZW, Ikenaga N, Liu SB, Sverdlov DY, et al
    Integrin alphavbeta6 critically regulates hepatic progenitor cell function and promotes ductular reaction, fibrosis and tumorigenesis.
    Hepatology. 2015 Oct 8. doi: 10.1002/hep.28274.
    PubMed     Text format     Abstract available


  154. PETTA S, Maida M, Macaluso FS, Di Marco V, et al
    The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease.
    Hepatology. 2015;62:1101-10.
    PubMed     Text format     Abstract available


    September 2015
  155. VILLANUEVA C, Albillos A, Genesca J, Abraldes JG, et al
    Development of hyperdynamic circulation and response to beta-blockers in compensated cirrhosis with portal hypertension.
    Hepatology. 2015 Sep 30. doi: 10.1002/hep.28264.
    PubMed     Text format     Abstract available


  156. FERNANDEZ-VARO G, Oro D, Cable EE, Reichenbach V, et al
    Vasopressin 1a receptor partial agonism increases sodium excretion and reduces portal hypertension and ascites in cirrhotic rats.
    Hepatology. 2015 Sep 24. doi: 10.1002/hep.28250.
    PubMed     Text format     Abstract available


  157. YOSHIMURA K, Okanoue T, Ebise H, Iwasaki T, et al
    Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining.
    Hepatology. 2015 Sep 21. doi: 10.1002/hep.28226.
    PubMed     Text format     Abstract available


  158. COUSIEN A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, et al
    Hepatitis c treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs.
    Hepatology. 2015 Sep 21. doi: 10.1002/hep.28227.
    PubMed     Text format     Abstract available


  159. BEUERS U, Gershwin ME, Gish RG, Invernizzi P, et al
    Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'.
    Hepatology. 2015 Sep 15. doi: 10.1002/hep.28140.
    PubMed     Text format    


  160. DE PIETRI L, Bianchini M, Montalti R, De Maria N, et al
    Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy. A randomized controlled trial.
    Hepatology. 2015 Sep 4. doi: 10.1002/hep.28148.
    PubMed     Text format     Abstract available


  161. BUTLER NS, Schmidt NW
    Erythropoietin-producing hepatocellular receptor B2 receptor tyrosine kinase: A novel regulator of infection- and inflammation-induced liver fibrosis.
    Hepatology. 2015;62:680-3.
    PubMed     Text format    


    August 2015
  162. GORHAM JD, Gleeson MW
    Cirrhosis and dysbiosis: New insights from next generation sequencing.
    Hepatology. 2015 Aug 27. doi: 10.1002/hep.28133.
    PubMed     Text format    


  163. TRIVEDI PJ, Corpechot C, Pares A, Hirschfield GM, et al
    Risk Stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists.
    Hepatology. 2015 Aug 20. doi: 10.1002/hep.28128.
    PubMed     Text format     Abstract available


  164. SHIMODA S, Hisamoto S, Harada K, Iwasaka S, et al
    Natural killer cells regulate T cell immune responses in primary biliary cirrhosis.
    Hepatology. 2015 Aug 11. doi: 10.1002/hep.28122.
    PubMed     Text format     Abstract available


  165. SILVA-JUNIOR G, Baiges A, Turon F, Torres F, et al
    The prognostic value of HVPG in patients with cirrhosis is highly dependent on the accuracy of the technique.
    Hepatology. 2015 Aug 3. doi: 10.1002/hep.28031.
    PubMed     Text format     Abstract available


  166. TOROK NJ, Dranoff JA, Schuppan D, Friedman SL, et al
    Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014.
    Hepatology. 2015;62:627-34.
    PubMed     Text format     Abstract available


  167. MCLAREN CE, Emond MJ, Subramaniam VN, Phatak PD, et al
    Exome sequencing in HFE C282Y homozygous men with extreme phenotypes identifies a GNPAT variant associated with severe iron overload.
    Hepatology. 2015;62:429-39.
    PubMed     Text format     Abstract available


    July 2015
  168. CARBONE M, Sharp SJ, Flack S, Paximadas D, et al
    The UK-PBC Risk Scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cirrhosis.
    Hepatology. 2015 Jul 29. doi: 10.1002/hep.28017.
    PubMed     Text format     Abstract available


  169. HENRY ZH, Northup PG
    Baclofen for the treatment of muscle cramps in patients with cirrhosis: A new alternative.
    Hepatology. 2015 Jul 14. doi: 10.1002/hep.27988.
    PubMed     Text format     Abstract available


  170. BAJAJ JS
    Liver Capsule: Hepatic Encephalopathy.
    Hepatology. 2015 Jul 14. doi: 10.1002/hep.27984.
    PubMed     Text format    


  171. KUMADA H, Chayama K, Rodrigues-Jr L, Suzuki F, et al
    Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir for HCV Genotype 1b-infected Japanese Patients With or Without Cirrhosis.
    Hepatology. 2015 Jul 3. doi: 10.1002/hep.27972.
    PubMed     Text format     Abstract available


  172. KAYADIBI H, Sertoglu E, Uyanik M
    Biochemical markers, liver biopsy, or magnetic resonance elastography to detect or exclude advanced fibrosis in patients with nonalcoholic fatty liver disease.
    Hepatology. 2015;62:324-5.
    PubMed     Text format    


    June 2015
  173. MANENTI A, Pavesi E, Farinetti A, Colasanto D, et al
    A morpho-dynamic evaluation of the portal and hepatic venous system in cirrhosis can predict a progression of portal hypertension.
    Hepatology. 2015 Jun 30. doi: 10.1002/hep.27967.
    PubMed     Text format    


  174. AQEL B, Pungpapong S, Leise M, Werner KT, et al
    Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis.
    Hepatology. 2015 Jun 11. doi: 10.1002/hep.27937.
    PubMed     Text format     Abstract available


  175. JIMENEZ CALVENTE C, Sehgal A, Popov Y, Kim YO, et al
    Specific hepatic delivery of procollagen alpha1(I) siRNA in lipid-like nanoparticles resolves liver fibrosis.
    Hepatology. 2015 Jun 10. doi: 10.1002/hep.27936.
    PubMed     Text format     Abstract available


  176. SAXENA V, Nyberg L, Pauly M, Dasgupta A, et al
    Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C Infected Patients with Compensated and Decompensated Cirrhosis.
    Hepatology. 2015 Jun 1. doi: 10.1002/hep.27922.
    PubMed     Text format     Abstract available


  177. PIND ML, Moller S, Faqir N, Bendtsen F, et al
    Predictive value of indocyanine green retention test and indocyanine green clearance in Child-Pugh class A patients.
    Hepatology. 2015;61:2112-3.
    PubMed     Text format    


  178. LISOTTI A, Azzaroli F, Mazzella G
    Reply: To PMID 24038116.
    Hepatology. 2015;61:2113-4.
    PubMed     Text format    


  179. THAPA M, Chinnadurai R, Velazquez VM, Tedesco D, et al
    Liver fibrosis occurs through dysregulation of MyD88-dependent innate B-cell activity.
    Hepatology. 2015;61:2067-79.
    PubMed     Text format     Abstract available


  180. KANTARI-MIMOUN C, Castells M, Klose R, Meinecke AK, et al
    Resolution of liver fibrosis requires myeloid cell-driven sinusoidal angiogenesis.
    Hepatology. 2015;61:2042-55.
    PubMed     Text format     Abstract available


    May 2015
  181. SULTANIK P, Sogni P, Meritet J, Pol S, et al
    Patients with Chronic Hepatitis B should be screened for Hepatocellular Carcinoma Regardless of Liver Stiffness Measurement.
    Hepatology. 2015 May 23. doi: 10.1002/hep.27904.
    PubMed     Text format    


  182. PATEL VC, Shawcross DL
    Salivary microbiota-immune profiling in cirrhosis: could this be the non-invasive strategy that will revolutionise prognostication in hepatology?
    Hepatology. 2015 May 22. doi: 10.1002/hep.27870.
    PubMed     Text format    


  183. KIM MN, Han KH, Kim SU
    Reply to "Patients with chronic hepatitis b should be screened for hepatocellular carcinoma regardless of liver stiffness measurement."
    Hepatology. 2015 May 20. doi: 10.1002/hep.27903.
    PubMed     Text format    


  184. SINN DH, Lee J, Goo J, Kim K, et al
    Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load.
    Hepatology. 2015 May 11. doi: 10.1002/hep.27889.
    PubMed     Text format     Abstract available


  185. ALQAHTANI SA, Afdhal N, Zeuzem S, Gordon S, et al
    Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hcv genotype 1 infection: Analysis of phase 3 ION trials.
    Hepatology. 2015 May 11. doi: 10.1002/hep.27890.
    PubMed     Text format     Abstract available


  186. EKSTEDT M, Hagstrom H, Nasr P, Fredrikson M, et al
    Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.
    Hepatology. 2015;61:1547-54.
    PubMed     Text format     Abstract available


  187. TORRES DM, Harrison SA
    Nonalcoholic fatty liver disease: Fibrosis portends a worse prognosis.
    Hepatology. 2015;61:1462-4.
    PubMed     Text format    


    April 2015
  188. LIN CL, Kao JH
    Can noninvasive biomarkers replace liver biopsy for chronic hepatitis B?
    Hepatology. 2015 Apr 24. doi: 10.1002/hep.27865.
    PubMed     Text format    


  189. XIAO G, Shen J, Yan L
    Reply: HEP-14-0182 Can noninvasive biomarkers replace liver biopsy for chronic hepatitis B?
    Hepatology. 2015 Apr 24. doi: 10.1002/hep.27861.
    PubMed     Text format    


  190. VAN DER MEER AJ
    Value anti-HCV therapy by its clinical efficacy.
    Hepatology. 2015 Apr 18. doi: 10.1002/hep.27850.
    PubMed     Text format    


  191. WU L, Zhao J
    Does IL-22 protect against liver fibrosis in hepatitis C virus infection?
    Hepatology. 2015 Apr 18. doi: 10.1002/hep.27856.
    PubMed     Text format    


  192. BUTT AA, Yan P, Bonilla H, Abou-Samra AB, et al
    Effect of addition of statins to antiviral therapy in HCV infected persons: Results from ERCHIVES.
    Hepatology. 2015 Apr 6. doi: 10.1002/hep.27835.
    PubMed     Text format     Abstract available


  193. KO E, Jung ES, Jung G
    Telomerase reverse transcriptase promoter methylation is related to a risk of recurrence in hepatocellular carcinoma.
    Hepatology. 2015 Apr 4. doi: 10.1002/hep.27833.
    PubMed     Text format    


  194. NAULT JC, Calderaro J, Zucman-Rossi J
    Response to "telomerase reverse transcriptase promoter methylation is related to a risk of recurrence in hepatocellular carcinoma" by Ko E and colleagues.
    Hepatology. 2015 Apr 4. doi: 10.1002/hep.27827.
    PubMed     Text format    


  195. SCHRAMM C, Wahl I, Lohse AW
    Reply.
    Hepatology. 2015;61:1435.
    PubMed     Text format    


    March 2015
  196. MILANO M, Aghemo A, Mancina RM, Fischer J, et al
    TM6SF2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients.
    Hepatology. 2015 Mar 29. doi: 10.1002/hep.27811.
    PubMed     Text format     Abstract available


  197. KITSON MT, Sarrazin C, Toniutto P, Roberts SK, et al
    Relationship between vitamin D status and response to HCV therapy.
    Hepatology. 2015 Mar 21. doi: 10.1002/hep.27797.
    PubMed     Text format    


  198. PINEDA-TENOR D, Garcia-Alvarez M, Jimenez-Sousa MA, Fernandez-Rodriguez A, et al
    Reply to Kitson et al.: "Relationship between vitamin D status and response to HCV therapy".
    Hepatology. 2015 Mar 21. doi: 10.1002/hep.27796.
    PubMed     Text format    


  199. MIMCHE PN, Brady LM, Bray CF, Mimche SM, et al
    The receptor tyrosine kinase EphB2 promotes hepatic fibrosis in mice.
    Hepatology. 2015 Mar 17. doi: 10.1002/hep.27792.
    PubMed     Text format     Abstract available


    February 2015
  200. INNES HA, McDonald SA, Dillon JF, Allen S, et al
    Towards a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes.
    Hepatology. 2015 Feb 26. doi: 10.1002/hep.27766.
    PubMed     Text format     Abstract available


  201. GHONEM NS, Assis DN, Boyer JL
    On fibrates and cholestasis: A review.
    Hepatology. 2015 Feb 11. doi: 10.1002/hep.27744.
    PubMed     Text format     Abstract available


  202. PANG Q, Sen Xu X, Zhang JY, Qu K, et al
    FIB-4 as a prognostic model for patients with hepatitis B-associated hepatocellular carcinoma.
    Hepatology. 2015 Feb 2. doi: 10.1002/hep.27727.
    PubMed     Text format    


    January 2015
  203. POUPON R
    Liver alkaline phosphatase: A missing link between choleresis and biliary inflammation.
    Hepatology. 2015 Jan 20. doi: 10.1002/hep.27715.
    PubMed     Text format     Abstract available


  204. CHAYAMA K, Notsumata K, Kurosaki M, Sato K, et al
    Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hcv-infected patients.
    Hepatology. 2015 Jan 16. doi: 10.1002/hep.27705.
    PubMed     Text format     Abstract available


  205. FALLOWFIELD DJ
    Macrophage-derived VEGF and angiogenesis within the hepatic scar - new pathways unmasked in the resolution of fibrosis.
    Hepatology. 2015 Jan 10. doi: 10.1002/hep.27696.
    PubMed     Text format    


  206. OBACH D, Yazdanpanah Y, Esmat G, Avihingsanon A, et al
    How to optimize HCV treatment impact on life years saved in resource-constrained countries.
    Hepatology. 2015 Jan 10. doi: 10.1002/hep.27691.
    PubMed     Text format     Abstract available


    December 2014
  207. MACIAS J, Mancebo M, Marquez M, Merino D, et al
    Low risk of liver decompensation among human immunodeficiency virus/hepatitis c virus-coinfected patients with mild fibrosis in the short-term.
    Hepatology. 2014 Dec 24. doi: 10.1002/hep.27674.
    PubMed     Text format     Abstract available


  208. SUH B, Park S, Shin DW, Yun JM, et al
    High liver fibrosis index FIB-4 highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers.
    Hepatology. 2014 Dec 12. doi: 10.1002/hep.27654.
    PubMed     Text format     Abstract available


  209. PAN RL, Xiang LX, Wang P, Liu XY, et al
    FGF2 attenuates hepatic fibrosis via epigenetic downregulation of Delta-like1.
    Hepatology. 2014 Dec 11. doi: 10.1002/hep.27649.
    PubMed     Text format     Abstract available


  210. O'MAHONY F, Wroblewski K, O'Byrne SM, Jiang H, et al
    Liver X receptors balance lipid stores in hepatic stellate cells via Rab18, a retinoid responsive lipid droplet protein.
    Hepatology. 2014 Dec 6. doi: 10.1002/hep.27645.
    PubMed     Text format     Abstract available


  211. CHIANG CJ, Yang YW, Chen JD, You SL, et al
    Significant reduction in end-stage liver diseases burden through national viral hepatitis therapy program in Taiwan.
    Hepatology. 2014 Dec 5. doi: 10.1002/hep.27630.
    PubMed     Text format     Abstract available


    October 2014
  212. SCORLETTI E, Bhatia L, McCormick KG, Clough GF, et al
    Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study.
    Hepatology. 2014;60:1211-21.
    PubMed     Text format     Abstract available


  213. CHEN RP, Chen C, Yu JY, Huang XL, et al
    Trial sequence meta-analysis can reject false-positive result calculated from conventional meta-analysis.
    Hepatology. 2014;60:1442-3.
    PubMed     Text format    


  214. BERNARDI M, Caraceni P, Navickis RJ, Wilkes MM, et al
    Reply: To PMID 22095893.
    Hepatology. 2014;60:1443-5.
    PubMed     Text format    


    August 2014
  215. DELEVE LD
    Liver sinusoidal endothelial cells in hepatic fibrosis.
    Hepatology. 2014 Aug 18. doi: 10.1002/hep.27376.
    PubMed     Text format     Abstract available


    May 2014
  216. LLEO A, Zhang W, McDonald WH, Seeley EH, et al
    Shotgun Proteomics: Identification of Unique Protein Profiles of Apoptotic Bodies from Biliary Epithelial Cells.
    Hepatology. 2014 May 20. doi: 10.1002/hep.27230.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: